Piperacillin/Tazobactam in critically ill morbidly obese patients: A case series: The first One-Centre experience with TDM

M Mieresova; K Balazova; J Kubele; D Cerny; M Halacova

doi:10.1002/ccr3.7032

Piperacillin/Tazobactam in critically ill morbidly obese patients: A case series: The first One-Centre experience with TDM

Clin Case Rep. 2023 Mar 11;11(3):e7032. doi: 10.1002/ccr3.7032. eCollection 2023 Mar.

Authors

M Mieresova^{1

2}, K Balazova¹, J Kubele³, D Cerny^{1

4}, M Halacova^{1

2}

Affiliations

¹ Department of Clinical Pharmacy Na Homolce Hospital Prague Czech Republic.
² Department of Pharmacology Motol University Hospital and 2nd Faculty of Medicine, Charles University Prague Czech Republic.
³ Department of Clinical Microbiology and Antibiotic Surveillance Na Homolce Hospital Prague Czech Republic.
⁴ Institute of Pharmacology, General University Hospital and 1st Faculty of Medicine, Charles University Prague Czech Republic.

Abstract

The aim of this article is to demonstrate extreme interindividual variability of piperacilin/tazobactam (PIP/TAZO) pharmacokinetics in critically ill morbidly obese patients and to emphasize the need for the practice of routine PIP/TAZO plasma concentrations measurement in order to ensure optimal efficacy and safety of antibiotic therapy.

Keywords: critical illness; morbid obesity; piperacillin/tazobactam (PIP/TAZO); therapeutic drug monitoring (TDM).

Publication types

Case Reports